{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:46:30Z","timestamp":1780080390413,"version":"3.54.0"},"reference-count":67,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Cachexia worsens prognosis, quality of life and chemotherapy treatment compliance of patients with lung cancer. Chemotherapy-induced cachexia has also been implicated in lowered mortality. This study aimed to evaluate the frequency of cachexia-related measures and symptoms as outcomes in lung cancer chemotherapy trial protocols and to examine how key trial characteristics influence them. Method: We conducted a cross-sectional data analysis of randomised controlled chemotherapy trials of lung cancer registered in four public trial registries between 2012 and 2023. Trial outcome measures included overall survival, treatment toxicity\/side effects and cachexia-related indicators such as physical activity, weight\/body mass index (BMI), dietary limitations, caloric intake and lean muscle mass. Symptom-related outcomes, including appetite loss, diarrhoea, pain, fatigue\/insomnia, constipation, nausea, vomiting, dysphagia, dyspnoea and oral mucositis, were also extracted. Additionally, the number and type of performance status and assessment tool were recorded. Data were summarised descriptively. Chi-square tests were used to examine associations between trial outcomes and characteristics including cancer type, trial location, lead investigator\/funding source, assessment tools and trial commencement year. A p &lt; 0.05 was considered statistically significance. Results: Of the 335 trial protocols (non-small cell (87.2%) and small cell (12.8%)), most were from Europe (50.4%). The trial lead investigator was from industry (56.7%) followed by academia (25.1%). Allied health professional involvement was minimal (0.6%). Trial protocols mostly recorded overall survival (96.4%) and toxicity (83.9%). However, physical activity, weight\/BMI, dysphagia, dyspnoea and oral mucositis were recorded in &lt;30%, with dietary limitations, caloric intake and lean muscle mass recorded in &lt;3% of the trials. Measures and symptoms were not associated with cancer type. Trial location was associated with the measures toxicity, physical activity and caloric intake and all symptoms. Lead investigator was associated with the measures toxicity and weight\/BMI and all symptoms except for dyspnoea. Performance status and assessment tools were mentioned in 93.4% and 41.8% of the trials, respectively, with significant associations between assessment tools and outcomes, except for weight\/BMI, dietary limitations, lean muscle mass, dysphagia and oral mucositis. There was a significant trend with trial commencement year for the measures physical activity (p = 0.002) and weight\/BMI (p = 0.000) and all symptoms, except for appetite loss (p = 0.115) and pain (p = 0.433). Conclusions: While the reporting of measures and outcomes was generally higher compared to gastrointestinal chemotherapy cancer trials, it still faced significant under-reporting. Assessment tools should include cachexia-specific symptoms to accurately assess the quality of life in patients with lung cancer undergoing chemotherapy clinical trials.<\/jats:p>","DOI":"10.3390\/cancers17142309","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:26:53Z","timestamp":1752229613000},"page":"2309","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["What Cachexia-Related Outcomes Are Measured in Lung Cancer Chemotherapy Clinical Trials?"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8975-0910","authenticated-orcid":false,"given":"Valentina","family":"Razmovski-Naumovski","sequence":"first","affiliation":[{"name":"School of Medicine, Western Sydney University (WSU), Sydney, NSW 2560, Australia"},{"name":"South West Sydney Clinical Campuses, Faculty of Medicine & Health, University of New South Wales (UNSW) Sydney, Sydney, NSW 2170, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Tanous","sequence":"additional","affiliation":[{"name":"Royal Brisbane and Women\u2019s Hospital, Queensland Health, Brisbane, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Valaire","sequence":"additional","affiliation":[{"name":"South West Sydney Clinical Campuses, Faculty of Medicine & Health, University of New South Wales (UNSW) Sydney, Sydney, NSW 2170, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024, June 06). Lung Cancer. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lung-cancer."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00520-014-2534-3","article-title":"Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer","volume":"23","author":"Kimura","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/ajcn\/83.4.735","article-title":"Cachexia: Pathophysiology and clinical relevance1, 2","volume":"83","author":"Morley","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/jcsm.12674","article-title":"Weight loss, malnutrition, and cachexia in COVID-19: Facts and numbers","volume":"12","author":"Anker","year":"2021","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: Understanding the molecular basis","volume":"14","author":"Busquets","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/1759-7714.12910","article-title":"Updates on the pathogenesis of advanced lung cancer-induced cachexia","volume":"10","author":"Zhu","year":"2019","journal-title":"Thorac. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Agar, M., and Razmovski-Naumovski, V. (2025). Cachexia, Anorexia, and Feeding Difficulties in Palliative Care Patients. Textbook of Palliative Care, Springer.","DOI":"10.1007\/978-3-031-48991-4_16"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/cam4.841","article-title":"An analysis of the relationship between metastases and cachexia in lung cancer patients","volume":"5","author":"Shiono","year":"2016","journal-title":"Cancer Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jpainsymman.2014.09.008","article-title":"Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer","volume":"49","author":"LeBlanc","year":"2015","journal-title":"J. Pain Symptom Manag."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Gilmore, L.A., Willmann, J., Olaechea, S., Gilmore, B.W., Dee, E.C., Rao, M., Gannavarapu, B.S., Venkateswaran, S., Alvarez, C.M., and Ahn, C. (2025). Prevalence and development of cachexia before and after diagnosis of non\u2013small cell lung cancer. Am. J. Clin. Oncol.","DOI":"10.1097\/COC.0000000000001211"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.21037\/tlcr-22-561","article-title":"The landscape of cancer cachexia in advanced non-small cell lung cancer: A narrative review","volume":"12","author":"Yamada","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7587","DOI":"10.4081\/ejtm.2018.7587","article-title":"Chemotherapy-induced muscle wasting: An update","volume":"28","author":"Coletti","year":"2018","journal-title":"Eur. J. Transl. Myol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Bossi, P., Delrio, P., Mascheroni, A., and Zanetti, M. (2021). The spectrum of malnutrition\/cachexia\/sarcopenia in oncology according to different cancer types and settings: A narrative review. Nutrients, 13.","DOI":"10.3390\/nu13061980"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00520-017-3593-z","article-title":"Predictors of the multidimensional symptom experience of lung cancer patients receiving chemotherapy","volume":"25","author":"Wong","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1038\/sj.bjc.6601781","article-title":"Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?","volume":"90","author":"Ross","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Go, S.-I., Park, M.J., and Lee, G.-W. (2021). Clinical significance of the cachexia index in patients with small cell lung cancer. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08300-x"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Naito, T., Okayama, T., Aoyama, T., Ohashi, T., Masuda, Y., Kimura, M., Shiozaki, H., Murakami, H., Kenmotsu, H., and Taira, T. (2017). Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non\u2013small-cell lung cancer. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3562-4"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.1007\/s00520-020-05689-2","article-title":"We report performance status in oncology-but not nutritional status?","volume":"28","author":"Aktas","year":"2020","journal-title":"Support. Care Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/jcsm.13458","article-title":"Are measures and related symptoms of cachexia recorded as outcomes in gastrointestinal cancer chemotherapy clinical trials?","volume":"15","author":"Valaire","year":"2024","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2011.09.012","article-title":"Pre-cachexia in patients with stages I\u2013III non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system","volume":"76","author":"Langen","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_21","first-page":"397","article-title":"Management of anorexia-cachexia in late stage lung cancer patients","volume":"14","author":"Grant","year":"2012","journal-title":"J. Hosp. Palliat. Nurs. JHPN Off. J. Hosp. Palliat. Nurses Assoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1186\/s13063-023-07730-1","article-title":"How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review","volume":"24","author":"Royle","year":"2023","journal-title":"Trials"},{"key":"ref_23","unstructured":"ClinicalTrials.gov (2025, June 28). US National Library of Medicine, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_24","unstructured":"(2025, June 28). Australia New Zealand Clinical Trials Registry. Available online: https:\/\/anzctr.org.au\/Default.aspx."},{"key":"ref_25","unstructured":"(2025, June 28). EU Clinical Trials Registry. Available online: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search."},{"key":"ref_26","unstructured":"Wu Taixiang, L.Y. (2025, June 28). Chinese Clinical Trial Registry. Available online: https:\/\/www.chictr.org.cn\/indexEN.html."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4103\/apjon.apjon_68_18","article-title":"Evaluation of the true endpoint of clinical trials for cancer cachexia","volume":"6","author":"Naito","year":"2019","journal-title":"Asia-Pac. J. Oncol. Nurs."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Campelj, D.G., Goodman, C.A., and Rybalka, E. (2021). Chemotherapy-induced myopathy: The dark side of the cachexia sphere. Cancers, 13.","DOI":"10.3390\/cancers13143615"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1002\/jcsm.13095","article-title":"Associations between body mass index, weight loss and overall survival in patients with advanced lung cancer","volume":"13","author":"Oswalt","year":"2022","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/jcsm.12625","article-title":"Weight loss over time and survival: A landmark analysis of 1000+ prospectively treated and monitored lung cancer patients","volume":"11","author":"Lopez","year":"2020","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_31","unstructured":"U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute (2024, August 25). Common Terminology Criteria for Adverse Events (CTCAE) v5.0, Available online: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: An international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cehreli, R., Yavuzsen, T., Ates, H., Akman, T., Ellidokuz, H., and Oztop, I. (2019). Can inflammatory and nutritional serum markers predict chemotherapy outcomes and survival in advanced stage nonsmall cell lung cancer patients?. BioMed Res. Int., 2019.","DOI":"10.1155\/2019\/1648072"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.clnu.2023.02.021","article-title":"Nutrition impact symptoms: Noteworthy prognostic indicators for lung cancer","volume":"42","author":"Liu","year":"2023","journal-title":"Clin. Nutr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/01635581.2019.1675720","article-title":"Nutritional status in patients with advanced lung cancer undergoing chemotherapy: A prospective observational study","volume":"72","author":"Lin","year":"2020","journal-title":"Nutr. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/1759-7714.15403","article-title":"Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: A retrospective study","volume":"15","author":"Doshita","year":"2024","journal-title":"Thorac. Cancer"},{"key":"ref_37","first-page":"73","article-title":"Fatigue in lung cancer patients: Symptom burden and management of challenges","volume":"7","author":"Carnio","year":"2016","journal-title":"Lung Cancer: Targets Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/jcsm.12967","article-title":"The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients","volume":"13","author":"Chargi","year":"2022","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jtho.2018.05.029","article-title":"Predictors of physical and functional loss in advanced-stage lung cancer patients receiving platinum chemotherapy","volume":"13","author":"Kinsey","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jpainsymman.2021.12.006","article-title":"Clinical decision support for symptom management in lung cancer patients: A group RCT","volume":"63","author":"Cooley","year":"2022","journal-title":"J. Pain Symptom Manag."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Islam, K., Anggondowati, T., Deviany, P., Ryan, J., Fetrick, A., Bagenda, D., Copur, M., Tolentino, A., Vaziri, I., and McKean, H. (2019). Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6054-x"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1007\/s00520-015-2699-4","article-title":"What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer","volume":"23","author":"LeBlanc","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jjco\/hyi230","article-title":"Weekly short infusion of taxotere at a 4 week cycle in Chinese patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based non-taxane chemotherapy\u2014A phase II trial","volume":"36","author":"Tsao","year":"2006","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.13189\/ojdom.2014.020104","article-title":"Oral health status in patients undergoing chemotherapy for lung cancer","volume":"2","author":"Konwinska","year":"2014","journal-title":"Open J. Dent. Oral Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4103\/apjon.apjon-219","article-title":"The psychosocial components of multimodal interventions offered to people with cancer cachexia: A scoping review","volume":"8","author":"Hopkinson","year":"2021","journal-title":"Asia-Pac. J. Oncol. Nurs."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/SPC.0000000000000241","article-title":"Practical multimodal care for cancer cachexia","volume":"10","author":"Maddocks","year":"2016","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/jcsm.12910","article-title":"Addressing unmet needs for people with cancer cachexia: Recommendations from a multistakeholder workshop","volume":"13","author":"Garcia","year":"2022","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.2010.33.4425","article-title":"Levels of symptom burden during chemotherapy for advanced lung cancer: Differences between public hospitals and a tertiary cancer center","volume":"29","author":"Cleeland","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","article-title":"Cancer progress and priorities: Lung cancer","volume":"28","author":"Schabath","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e001021","DOI":"10.1136\/esmoopen-2020-001021","article-title":"Lung cancer symptoms at diagnosis: Results of a nationwide registry study","volume":"5","author":"Provencio","year":"2020","journal-title":"ESMO Open"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejon.2010.01.003","article-title":"Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy","volume":"14","author":"Akin","year":"2010","journal-title":"Eur. J. Oncol. Nurs."},{"key":"ref_52","unstructured":"European Commission-European Cancer Information System (2025, June 28). 2022 New Cancer Cases and Cancer Deaths on the Rise in the EU. Available online: https:\/\/ecis.jrc.ec.europa.eu\/sites\/default\/files\/2024-01\/jrc_CancerEstimates2022_factsheet.pdf."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"10732748221095955","DOI":"10.1177\/10732748221095955","article-title":"Cancer incidence and mortality in Asian countries: A trend analysis","volume":"29","author":"Huang","year":"2022","journal-title":"Cancer Control"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"King","year":"2018","journal-title":"Patient Relat. Outcome Meas."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3332\/ecancer.2020.1132","article-title":"Research on lung cancer and its funding, 2004\u20132018","volume":"14","author":"Begum","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jtho.2016.03.010","article-title":"The state of lung cancer research: A global analysis","volume":"11","author":"Aggarwal","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.lungcan.2015.01.024","article-title":"Does lung cancer attract greater stigma than other cancer types?","volume":"88","author":"Marlow","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/JTO.0b013e3181622c17","article-title":"Prevalence of poor performance status in lung cancer patients: Implications for research","volume":"3","author":"Lilenbaum","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.6004\/jnccn.2014.0098","article-title":"Management of patients with lung cancer and poor performance status","volume":"12","author":"Gajra","year":"2014","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/oxfordjournals.jjco.a023195","article-title":"Retrospective analysis of the treatment of patients with small cell lung cancer showing poor performance status","volume":"26","author":"Sakuragi","year":"1996","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"CMO-S30891","DOI":"10.4137\/CMO.S30891","article-title":"Cachexia index in advanced non-small-cell lung cancer patients","volume":"9","author":"Jafri","year":"2015","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Fiteni, F., Anota, A., Westeel, V., and Bonnetain, F. (2016). Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: A critical review. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2152-1"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00520-014-2148-9","article-title":"Effect of chemotherapy on quality of life in patients with non-small cell lung cancer","volume":"22","author":"Mannion","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1007\/s00520-015-2606-z","article-title":"Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS)","volume":"23","author":"LeBlanc","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/jcsm.13571","article-title":"Detection of cancer-associated cachexia in lung cancer patients using whole-body [18F] FDG-PET\/CT imaging: A multi-centre study","volume":"15","author":"Ferrara","year":"2024","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"100282","DOI":"10.1016\/j.advnut.2024.100282","article-title":"Prevalence of and survival with cachexia among patients with cancer: A systematic review and meta-analysis","volume":"15","author":"Takaoka","year":"2024","journal-title":"Adv. Nutr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1245\/s10434-021-10406-2","article-title":"Impact of the COVID-19 pandemic on cancer clinical trials","volume":"28","author":"Boughey","year":"2021","journal-title":"Ann. Surg. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/14\/2309\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:08:26Z","timestamp":1760033306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/14\/2309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":67,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["cancers17142309"],"URL":"https:\/\/doi.org\/10.3390\/cancers17142309","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]}}}